Guillain-Barré Syndrome (GBS)

Therapeutic challenges in Guillain-Barré syndrome (GBS) include rapid disease progression requiring timely intervention and heterogeneity in patient responses to standard therapies. At Protheragen, we are committed to advancing the understanding and management of GBS through cutting-edge therapeutic development and disease modeling services. Our goal is to provide end-to-end solutions for the entire process from GBS therapeutic research to commercialization.

Introduction to Guillain-Barré Syndrome (GBS)

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy characterized by rapid-onset muscle weakness, areflexia, and sensory disturbances, often progressing to paralysis. With an incidence of 1-2 cases per 100,000 annually, GBS represents a neurological emergency requiring prompt intervention. The disease typically follows a monophasic course, peaking within 2-4 weeks, unlike its chronic counterpart, CIDP.

Fig.1 Pathophysiology of COVID-19 related Guillain-Barré syndrome (GBS). (Valaparla V L, et al., 2024)

Pathogenesis of Guillain-Barré Syndrome (GBS)

The pathogenesis of Guillain-Barré syndrome (GBS) is primarily driven by molecular mimicry, where microbial antigens trigger cross-reactive autoantibodies against peripheral nerve components, particularly gangliosides. These autoantibodies activate complement cascades, leading to formation of membrane attack complexes (C5b-9) that disrupt nodes of Ranvier and induce either demyelination or direct axonal injury. Concurrent T-cell infiltration and pro-inflammatory cytokine release exacerbate nerve damage, while genetic factors influence disease susceptibility and severity.

Fig.2 Immunopathological mechanisms involved in Guillain-Barré syndrome (GBS). (Shastri A, et al., 2023)

Therapeutic Development for Guillain-Barré Syndrome (GBS)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Recognizing the complexity of diagnosing and treating Guillain-Barré syndrome (GBS), Protheragen is committed to building a team of experts to provide cutting-edge diagnostic and therapeutic development solutions. Our commitment lies in providing a variety of customized therapy development services to meet the diverse research needs of our customers. We also excel in generating precise disease models that are carefully engineered to replicate the unique features of GBS.

Therapeutic Development Services

By Molecule Types

• Small Molecule Drug Development
• Cell Therapy Development
• Gene Therapy Development

• Therapeutic Antibody Development
• Therapeutic Peptide Development
• Therapeutic Protein Development

By Mechanism of Action

• Neuroprotective Agent Development
• Glutamate Modulator Development
• Anti-neuroinflammatory Drug Development
• Antioxidant Development

• Mitochondria-targeted Drug Development
• Protein Misfolding Inhibitor Development
• Protein Aggregation Inhibitor Development
• Excitotoxicity Inhibitor Development

Disease Model Development Services

In Vitro Model Development

• Patient-Derived Cell Model
• Neuronal Cell Model
• Glial Cell Model
• Co-Culture Model
• Brain Organoid
• Spinal Cord Organoid

Microfluidic Model Development

• Neurovascular Unit (NVU) Model
• Axon Degeneration Model
• Neuroinflammation Model
• Neuromuscular Junction (NMJ) Model
• Synaptic Plasticity Model
• Organoid-on-a-Chip Model

Animal Model Development

• Experimental Autoimmune Neuritis (EAN) Model
• Campylobacter jejuni Induced Model
• Rabbit Anti-GalC Model
• FcγRIIB-KO Mouse Model
• L31 Mouse Model
• Other Models